about
The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infectionSynopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and ImmunotherapyImmunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression.Effects of TGF-beta on the immune system: implications for cancer immunotherapy.Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors.Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaSuppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy.Emerging strategies in tumor vaccines.Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection.Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMaxThe efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors.Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides.Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumoursLangerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:CHuman papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.Mechanisms used by human papillomaviruses to escape the host immune response.The evolving field of human papillomavirus receptor research: a review of binding and entry.Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis.Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro.Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.Notch-ing from T-cell to B-cell lymphoid malignancies.Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability.Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.
P50
Q21134079-2F4CBD4D-73A7-401B-8ED7-3E921DDC699BQ24798754-FC4CFB25-7550-4D3D-8118-8670105BAD9BQ27307719-E8CA3A6A-E07D-447C-AD44-A820FF7EB2B8Q33582300-75493E9F-0476-44F2-8134-D193FEE8D822Q33604135-093CC3C8-D801-4968-A129-A53899657766Q33611998-91C0EDD5-C324-4318-851B-5F09F3CD0BECQ33694988-152394DF-AB3A-421F-B872-3A963C7FCD1AQ33713481-B20464D9-7A2E-4EF7-A2A4-843A1ADF576CQ33752878-02B15938-FC3E-4761-B73E-92418BE5D6ADQ34181909-3BBAA170-4A45-47CE-90F5-3B2F63EB98D8Q34181954-6CACB2F6-3D3D-446B-B88F-8E95665678FEQ34408919-40B991B6-DF8C-4C02-AF09-DA9EB12D0AB8Q34956064-E557BBBE-46CA-48D7-B76D-8C2D1D793182Q34985272-4D7B9067-71C8-4439-845A-33842CC7C50BQ35013272-EEDEC515-F44F-4DC2-8249-29B7165133F0Q35662068-C762C320-8837-490E-9FAE-8DBF1E241DD9Q35790603-EAD3F095-D45B-4B3D-9746-5C66B0F5A346Q35828417-5DC6C0C2-665C-4E71-9BA1-BDF8E3651DDEQ35865140-8BD7A8AE-AB83-492D-ABD2-0654E0AC4388Q35922431-781E6645-F10B-42FF-B354-A7A0B30647C3Q36255133-AB494377-85BC-47F4-8FC7-99703037BA50Q36315857-09C12E47-927F-417E-800A-0789E17DAC90Q36350381-591D6736-7A30-4E32-8334-DBDAB730C9DFQ36720700-7DDC8512-25C4-4306-8FE4-9F6E02478A9AQ36737715-DC894B00-9F75-4527-9A98-3E52C79D4296Q36827213-1E1256EC-EABD-4E47-87CE-1AE7D5476A87Q36844954-29C415C2-0643-4F8C-942B-FD1BAD39F6A1Q36987072-6E4C6E98-402F-4415-BF4B-B0DF027C1961Q37102101-68F6A36C-7995-491D-A395-A63823470658Q37135023-196D0B3F-34C8-4859-8538-39E62FBE8731Q37349884-FBBD515B-4ECC-454B-B249-BC77096E013EQ37374278-731C3FDA-61B6-478B-AF57-D62D56AC3439Q37415380-5C485380-86AF-4920-B227-6D179AB42D2CQ37423972-78874DE7-223E-44C8-B606-A81F5B1F4ED0Q37873924-A9DD8AC0-6F8E-48AA-A687-3454D6BA85A2Q37873930-066CEF8C-2662-4896-A1DB-3A5F628D7DD0Q37886330-15FA76B3-18F7-46C0-AE6B-BA016D444D64Q38053488-E1C946EA-ACDA-4B7C-AFE2-89E0E2D8C4D3Q39304645-FF6E547C-59F1-4A71-AC5B-3EF7552A9567Q39900144-8FDFCA8E-6666-4EF2-BC2F-FE667CFB5A95
P50
subject
description
Forscher
@de
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究員
@ja
研究者
@zh
name
W M Kast
@en
W M Kast
@nl
type
label
W M Kast
@en
W M Kast
@nl
prefLabel
W M Kast
@en
W M Kast
@nl
P106
P31
P496
0000-0003-2321-3159